Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: Extended follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus)

Pharmacotherapy

Volumn 25, Issue 1, 2005, Pages 110-115

  Yamada, Carol ^a   Johnson, Jeffrey A ^b   Robertson, Patrick ^c   Pearson, Glen ^b   Tsuyuki, Ross T ^b,d  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROYAL UNIVERSITY HOSPITAL   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular risk; Cholesterol; Community pharmacist intervention; Coronary heart disease; LDL; Low density lipoprotein cholesterol

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PHARMACY; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHARMACIST; RISK REDUCTION;

AGED; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL; COMMUNITY PHARMACY SERVICES; DRUG THERAPY; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, LDL; MALE; PATIENT EDUCATION; PATIENT SELECTION; PHARMACISTS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 11144245656     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.1.110.55619     Document Type: Article

References (18)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
7. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
8. Olson KL, Bungard TJ, Tsuyuki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy 2001;21:807-17.
9. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-17.
10. Tsuyuki RT, Johnson JA, Teo KK, et al. Study of cardiovascular risk intervention by pharmacists (SCRIP): A randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacotherapy 1999;33:910-19.
11. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management. Arch Intern Med 2002;162:1149-55.
12. Tsuyuki RT, Olson KL, Dubyk AM, Schindel T, Johnson JA. Effect of a community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Am J Med 2004;116:130-3.
13. Fodor JG, Frohlich JJ, Genest JJG Jr, et al. Recommendations for the management and treatment of dyslipidemia: report of the working group on hypercholesterolemia and other dyslipidemias. Can Med Assoc J 2000;162:1441-7.
14. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
15. Benner JS, Glynn FJ, Jogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
16. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
17. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. Pharmacotherapy 2000;20:1508-16.
18. Simpson SH, Johnson JA, Biggs C, et al. Practiced-based research: lessons from community pharmacist participants. Pharmacotherapy 2001;21:731-9.